Two Analysts Like Syndax's Breast Cancer Drug By: Benzinga via Benzinga March 28, 2016 at 08:39 AM EDT Morgan Stanley’s Matthew Harrison initiated coverage of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with an Overweight rating and ... Read More >> Related Stocks: Syndax Pharma